Monitoring Report 2018: chapter 7 figures

Slides:

Advertisements

Similar presentations

Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans,

Advertisements

Immunodeficiency, not viremia, is a risk factor for non-AIDS defining malignancies in patients on cART Anouk Kesselring, Luuk Gras, Colette Smit, Frank.

CHARTERED: Dutch Clubs English Clubs Area J1 De Sprekers (A’dam) Sprekersgilde (A’dam) T. Epe (Heerde) Almere Orange T. Eindhoven Area J2 Amsterdam Taste.

HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,

Integrating Academic Hospital and Faculty of Medicine Prof. M. Džoljić Academic Medical Center University of Amsterdam, The Netherlands.

Evolution of DHC in The Netherlands Klaas de Jong, June 11 th 2014, Copenhagen.

Cascade of HIV Care in the Netherlands from 2002 to Esther Engelhard 14th European AIDS Conference October 18, 2013 Disclosed no conflict of interest.

Chapter 1: An Overview of the HIV/AIDS Epidemic Module 1, Chapter 1.

Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.

Progress toward COP 12 targets Mozambique-ICB October

BHIVA Audit Survey of patient assessment and monitoring Set-up phase of cohort audit of patients starting ART from naïve.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

Scaling-up male circumcision programmes in the Eastern and Southern Africa Region Country update meeting HIV Testing and Counseling and Male Circumcision.

The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.

Does HIV serosorting increase syphilis prevalence among men who have sex with men in Western Europe? - A mathematical modelling study.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.

Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.

Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.

1 MSM Sexual Health Summit August 20, 2012 HIV/STD Prevention and Care Branch Texas Department of State Health Services.

Annual Epidemiological Spotlight on HIV in London: 2014 data Field Epidemiology Services PHE Publications gateway number

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Progress toward COP 12 targets DRC October

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.

All figures of the Monitoring Report 2014 This PowerPoint contains all figures of the Monitoring Report 2014, including those from the Web Appendix. When.

Sandra Ferns, on behalf of the LOTUS study group

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.

Summary of HIV Infection in Alaska, 1982–2015 Prepared by the State of Alaska Department of Health and Social Services, Division of Public Health, HIV/STD.

Making It Happen! The Global Outcomes Benchmarking (GLOBE) Program May 16, 2016.

HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2016.

Effects of a comprehensive community-based lifestyle intervention in patients with coronary artery disease: the trial.

Effects of a comprehensive community-based lifestyle intervention in patients with coronary artery disease: the trial.

Treatment-Naïve Adults

Abstract MOAB0301 Hepatitis C Care Cascade for People Living With HIV in the Country of Georgia Nikoloz Chkhartishvili1, A. Abutidze1, N. Bolokadze1, O.

San Antonio Breast Cancer Symposium. December

NVALT25/ELDAPT Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy.

undetectable (undetectable-6.25)

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

The DARE trial (Drug-eluting bAlloon for in-stent Restenosis)

HIV surveillance in Northern Ireland 2015

OUTREACH – Our most essential calling - 15 October 2016

A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova

From: Parvovirus B19–Related Anemia in an HIV-Infected Patient: Rapid Control after Production of Neutralizing Antibodies during Highly Active Antiretroviral.

AIDS supplement.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Table 1: New HIV diagnoses, by UK country,

HIV surveillance in Northern Ireland 2014

Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.

All figures of the Monitoring Report 2015

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

All figures of the Monitoring Report 2018

HIV/AIDS Surveillance in Europe 2011 HIV/AIDS Surveillance in Europe

Future challenges for clinical care of an ageing population infected with HIV: a modelling study Dr Mikaela Smit, PhD, Kees Brinkman, MD, Suzanne Geerlings,

HIV/AIDS Training for Health Facility Employees

CHAPTER 10 Hepatitis on Dialysis

HIV surveillance in Northern Ireland 2018

Baseline Kidney Function as Predictor of Mortality and Kidney Disease Progression in HIV-Positive Patients Fowzia Ibrahim, MSc, Lisa Hamzah, MRCP, Rachael.

Қош келдіңіздер.

Factors related to the chronicity and evolution of hepatitis C infection in patients coinfected by the human immunodeficiency virus R. Pérez-Cano, C.

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Volume 373, Issue 9672, Pages (April 2009)

HIV, STIs and Hepatitis among men who have sex with men (MSM) in Ireland October provisional data.

Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies J.C. Martín, V Soriano,

Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: Report of the Dutch Cutaneous Lymphoma Group Melchers RC1, Willemze.

MSM Attending STD Clinics HIV Testing More Frequently: Implications for HIV Prevention and Surveillance D Helms1, H Weinstock1, K Mahle1, A Shahkolahi1,2,

On behalf of the H-TEAM initiative

Share your thoughts on this presentation with #IAS2019

Presentation transcript:

Monitoring Report 2018: chapter 7 figures When using any of these figures, please include “Source: Stichting HIV Monitoring; Monitoring Report 2018” as a reference. The full report should be cited as follows: van Sighem A.I., Boender T.S., Wit F.W.N.M., Smit C., Matser A., Reiss P. Monitoring Report 2018. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. Amsterdam: Stichting HIV Monitoring, 2018. Available online at www.hiv-monitoring.nl

HIV treatment centres in the Netherlands 1 Noordwest Ziekenhuisgroep Alkmaar 2 Flevoziekenhuis Almere 3 Academic Medical Center of the University of Amsterdam (AMC-UvA) Amsterdam 4 DC Klinieken Lairesse – HIV Focus Centrum 5 OLVG 6 MC Slotervaart 7 Medisch Centrum Jan van Goyen (MC Jan van Goyen) 8 VUmc 9 Rijnstate Arnhem 10 HagaZiekenhuis (Leyweg site) Den Haag 11 HMC (Haaglanden Medisch Centrum) 12 Catharina Ziekenhuis Eindhoven 13 Medisch Spectrum Twente (MST) Enschede 14 Admiraal De Ruyter Ziekenhuis Goes 15 Universitair Medisch Centrum Groningen (UMCG) Groningen 16 Spaarne Gasthuis Haarlem 17 Medisch Centrum Leeuwarden (MCL) Leeuwarden 18 Leids Universitair Medisch Centrum (LUMC) Leiden 19 MC Zuiderzee Lelystad 20 Maastricht UMC+ (MUMC+) Maastricht 21 Radboudumc Nijmegen 22 Erasmus MC Rotterdam 23 Maasstad Ziekenhuis 24 ETZ (Elisabeth-TweeSteden Ziekenhuis) Tilburg 25 Universitair Medisch Centrum Utrecht (UMC Utrecht) Utrecht 26 Isala Zwolle A Emma Kinderziekenhuis (EKZ), AMC-UvA B Beatrix Kinderziekenhuis (BKZ), UMCG C Erasmus MC-Sophia Kinderziekenhuis D Wilhelmina Kinderziekenhuis (WKZ), UMC Utrecht

Figure 7.1 Annual number of individuals newly entering care per HIV treatment centre in the Netherlands in 2012-2017. Legend: IQR=interquartile range.

Figure 7.2A Retention in care: (A) 18 months after entering care, over time by year of entering care and (B) by HIV transmission group and patients’ region of origin, C) in 2017 for those who entered care between 2012-2015. Legend: IQR=interquartile range.

Figure 7.2B Retention in care: (A) 18 months after entering care, over time by year of entering care and (B) by HIV transmission group and patients’ region of origin, C) in 2017 for those who entered care between 2012-2015. Legend: IQR=interquartile range.

Figure 7.2C Retention in care: (A) 18 months after entering care, over time by year of entering care and (B) by HIV transmission group and patients’ region of origin, C) in 2017 for those who entered care between 2012-2015. Legend: IQR=interquartile range.

Figure 7.3A The proportion of patients who entered care between 2012-2016 and started combination antiretroviral therapy (cART) within six months after entry: (A) overall and (B) by CD4 cell count at entry, (C) the proportion with newly entered care between 2012-2016 and who initiated cART and were still in care in 2017. Legend: IQR=interquartile range.

Figure 7.3B The proportion of patients who entered care between 2012-2016 and started combination antiretroviral therapy (cART) within six months after entry: (A) overall and (B) by CD4 cell count at entry, (C) the proportion with newly entered care between 2012-2016 and who initiated cART and were still in care in 2017. Legend: IQR=interquartile range.

Figure 7.3C The proportion of patients who entered care between 2012-2016 and started combination antiretroviral therapy (cART) within six months after entry: (A) overall and (B) by CD4 cell count at entry, (C) the proportion with newly entered care between 2012-2016 and who initiated cART and were still in care in 2017. Legend: IQR=interquartile range.

Figure 7.4 Proportion of treatment-naive patients with a plasma HIV RNA level <400 copies/ml at 6 months (minimum and maximum: 3-9 months) after the start of combination antiretroviral therapy (cART) across all HIV treatment centres. Legend: IQR=interquartile range.

Figure 7.5A (A) The proportion of all HIV-positive patients in care who had been on combination antiretroviral therapy (cART) for at least 6 months and who had an HIV RNA level <100 copies/ml. This indicator was calculated for each calendar year during the period 2012-2017 and is presented as the proportion across all HIV treatment centres. Legend: IQR=interquartile range.

Figure 7.5B (B) The proportion of HIV-positive patients in care who entered care between 2012-2016 and who were still in care in 2017 with an HIV RNA level <100 copies/ml. Legend: IQR=interquartile range.

Figure 7.6A Proportion of patients who newly entered care in Dutch HIV treatment centres in 2012-2016, with assessment within six months of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, (D) total cholesterol in patients aged ≥50 years at entry in care, (E) hepatitis C, and (F) hepatitis B.

Figure 7.6B Proportion of patients who newly entered care in Dutch HIV treatment centres in 2012-2016, with assessment within six months of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, (D) total cholesterol in patients aged ≥50 years at entry in care, (E) hepatitis C, and (F) hepatitis B.

Figure 7.6C Proportions of patients who newly entered care in Dutch HIV treatment centres in 2012-2015, with assessment within six months of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, (D) total cholesterol in patients aged ≥50 years at entry in care, (E) hepatitis C, and (F) hepatitis B.

Figure 7.6D Proportions of patients who newly entered care in Dutch HIV treatment centres in 2012-2015, with assessment within six months of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, (D) total cholesterol in patients aged ≥50 years at entry in care, (E) hepatitis C, and (F) hepatitis B.

Figure 7.6E Proportions of patients who newly entered care in Dutch HIV treatment centres in 2012-2015, with assessment within six months of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, (D) total cholesterol in patients aged ≥50 years at entry in care, (E) hepatitis C, and (F) hepatitis B. Legend: HCV=hepatitis C.

Figure 7.6F Proportions of patients who newly entered care in Dutch HIV treatment centres in 2012-2015, with assessment within six months of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, (D) total cholesterol in patients aged ≥50 years at entry in care, (E) hepatitis C, and (F) hepatitis B. Legend: HBV=hepatitis B.

Figure 7.7A Proportions of patients in HIV treatment centres in the Netherlands who initiated combination antiretroviral therapy (cART) in 2012-2016, with assessment of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, and (D) total cholesterol in patients aged ≥50 years at entry in care within 13 months after start of cART.

Figure 7.7 B Proportions of patients in HIV treatment centres in the Netherlands who initiated combination antiretroviral therapy (cART) in 2012-2016, with assessment of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, and (D) total cholesterol in patients aged ≥50 years at entry in care within 13 months after start of cART.

Figure 7.7 C Proportions of patients in HIV treatment centres in the Netherlands who initiated combination antiretroviral therapy (cART) in 2012-2016, with assessment of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, and (D) total cholesterol in patients aged ≥50 years at entry in care within 13 months after start of cART.

Figure 7.7 D Proportions of patients in HIV treatment centres in the Netherlands who initiated combination antiretroviral therapy (cART) in 2012-2016, with assessment of (A) HIV RNA, (B) plasma CD4 cell count, (C) total cholesterol in patients aged <50 years at entry in care, and (D) total cholesterol in patients aged ≥50 years at entry in care within 13 months after start of cART.

Figure 7.8 Rates of repeat screening for hepatitis C virus (HCV) among men who have sex with men (MSM) who were HCV-negative at entry into care and for syphilis among all MSM who entered care in one of the HIV treatment centres in 2012 and 2015. MSM=men who have sex with men; HCV=hepatitis C; IQR=interquartile range.